Get started
Author

Belén Sola-Barrado

Observed names: B. Sola-Barrado, Belen Sola-Barrado, Belen Solar
ORCID: 0000-0003-0352-7396
Observed ORCID: 0000-0003-0352-7396
OpenAlex ID: A5046937940
Combinatorial Intracellular Delivery Screening of Anticancer Drugs
2020 · Belen Sola-Barrado, Diana M. Leite, et al. · Molecular Pharmaceutics · 14
HTA submission strategies and their associations with rollout times and type of HTA recommendation in Australia and Canada
2026 · Belen Sola-Barrado, Ting Wang, et al. · International Journal of Technology Assessment in Health Care · 1
PDF
PD63 Impact Of Parallel Submission On The Rollout Time and Health-Technology-Assessment Recommendation Of New-Active-Substances
2022 · Belen Sola-Barrado, Tina Wang, et al. · International Journal of Technology Assessment in Health Care · 1
PDF
OD08 Health Technology Assessment Timelines And Outcomes Of Common Compounds In France, Germany, Sweden, And Poland From 2014 To 2022
2024 · Belen Sola-Barrado, Tina Wang, et al. · International Journal of Technology Assessment in Health Care
PDF
OP136 A Comparison Of Health Technology Assessment Recommendations In Australia, Canada, And England: Is There Opportunity For Further Alignment?
2023 · Tina Wang, Belen Solar, et al. · International Journal of Technology Assessment in Health Care
PDF
HTA45 Study of HTA Timelines and Outcomes for MHRA-Approved NASs in the Post-Brexit UK via Reliance/Work-Sharing Routes
2023 · B. Sola-Barrado, T. Wang, et al. · Value in Health
PD47 Associations Of Orphan Designation And Other Drug Development-Related Factors On Rollout Times And Health-Technology-Assessment Recommendations Of New-Active-Substances
2022 · Belen Sola-Barrado, Tina Wang, et al. · International Journal of Technology Assessment in Health Care
PDF
Works count: 7
Citation count: 16
H-index: 1
I10-index: 1
Year
Topic
Type